Capecitabine Alternatives Compared
| Capecitabine | Ibrance | Enhertu |
|
|---|
| Capecitabine | Ibrance (palbociclib) | Enhertu (fam-trastuzumab deruxtecan) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Colorectal Cancer, Breast Cancer - Metastatic, Pancreatic Cancer, Breast Cancer, Anal Cancer, Stomach Cancer, Esophageal Carcinoma, Non Small Cell Lung Cancer, Prostate Cancer, Renal... View more |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Non Small Cell Lung Cancer, Solid Tumors, Breast Cancer, Gastric Cancer. Enhertu may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
Popular comparisons
|
|||||||||||||||||||||||
| More about Capecitabine | More about Ibrance (palbociclib) | More about Enhertu (fam-trastuzumab deruxtecan) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Capecitabine has an average rating of 6.5 out of 10 from a total of 57 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 28% reported a negative effect. |
Ibrance has an average rating of 6.7 out of 10 from a total of 82 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 30% reported a negative effect. |
Enhertu has an average rating of 8.0 out of 10 from a total of 23 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 5% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: capecitabine side effects in more detail. |
See also: Ibrance side effects in more detail. |
See also: Enhertu side effects in more detail. |
||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all capecitabine prices |
View all Ibrance prices |
View all Enhertu prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Xeloda |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
0.75 hours |
29 hours |
136.8 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 270 drugs are known to interact with capecitabine:
|
A total of 454 drugs are known to interact with Ibrance:
|
A total of 159 drugs are known to interact with Enhertu:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 30, 1998 |
February 03, 2015 |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.